

MarÃ-a Del Mar Tormo DÃ-az

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2213607/publications.pdf>

Version: 2024-02-01

67
papers

1,499
citations

471371

17
h-index

330025

37
g-index

69
all docs

69
docs citations

69
times ranked

1965
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances, 2022, 6, 882-890.	2.5	15
2	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma, 2022, 63, 538-550.	0.6	8
3	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Advances, 2022, 6, 1278-1295.	2.5	29
4	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers, 2022, 14, 1734.	1.7	13
5	Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Expert Review of Hematology, 2022, 15, 203-214.	1.0	3
6	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. Leukemia Research, 2022, 115, 106821.	0.4	3
7	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	6.9	26
8	An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.. Journal of Clinical Oncology, 2022, 40, TPS7063-TPS7063.	0.8	3
9	Evolving treatment patterns and outcomes in older patients (>=60 years) with AML: changing everything to change nothing?. Leukemia, 2021, 35, 1571-1585.	3.3	12
10	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	2.5	18
11	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer, 2021, 127, 2003-2014.	2.0	16
12	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	1.7	7
13	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia and Lymphoma, 2021, 62, 2727-2736.	0.6	0
14	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.	1.2	7
15	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematological Oncology, 2021, 39, 529-538.	0.8	3
16	Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. British Journal of Haematology, 2021, , .	1.2	2
17	Adverse prognostic impact of complex karyotype (>=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.4	11
18	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. Blood, 2021, 138, 3486-3486.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	1.7	2
20	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	1.7	29
21	Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 963-969.	0.8	6
22	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	3.3	54
23	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	0.6	15
24	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide: an International Collaborative Study. <i>Leukemia</i> , 2020, 34, 2333-2341.	3.3	20
25	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.2	5
26	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020, 105, 138-147.	1.1	12
27	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , 2020, 99, 527-537.	0.8	11
28	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
29	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , 2019, 39, 4757-4766.	0.5	3
30	Cytomegalovirus DNAemia in patients with <i>de novo</i> acute myeloid leukemia undergoing cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3081-3083.	0.6	0
31	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	1.2	6
32	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016.	0.5	3
33	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	1.7	17
34	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with <i>de novo</i> acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	0.6	12
35	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10.	0.4	15
36	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	1.1	14
38	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. <i>Blood</i> , 2019, 134, 648-648.	0.6	1
39	Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. <i>Leukemia and Lymphoma</i> , 2018, 59, 2383-2393.	0.6	1
40	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , 2018, 61, 206-212.	1.8	15
41	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018, 105, 139-143.	0.9	2
42	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. <i>Oncotarget</i> , 2018, 9, 19342-19355.	0.8	15
43	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018, 132, 4299-4299.	0.6	0
44	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Leukemia and Lymphoma</i> , 2017, 58, 145-152.	0.6	7
45	Oxidative imbalance in low/intermediate-risk myelodysplastic syndrome patients: The influence of iron overload. <i>Clinical Biochemistry</i> , 2017, 50, 911-917.	0.8	18
46	Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. <i>Oncotarget</i> , 2016, 7, 30492-30503.	0.8	41
47	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.	0.8	20
48	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. <i>Leukemia Research</i> , 2016, 41, 12-20.	0.4	41
49	An ex vivo native environment precision medicine AML test and the correlation with responses to 1st line treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18510-e18510.	0.8	0
50	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. <i>American Journal of Clinical Pathology</i> , 2015, 144, 484-492.	0.4	13
51	Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7061-7061.	0.8	0
52	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Cancer</i> , 2014, 120, 3958-3964.	2.0	24
53	Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1595-1604.	0.8	227
54	Clinical Significance of Myelofibrotic (MF) Changes in Myelodysplastic Syndromes (MDS): A Prospective Evaluation Including Mutational Analysis By Next-Generation Sequencing (NGS). <i>Blood</i> , 2014, 124, 4652-4652.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	0.6	2
56	The lincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. <i>Blood</i> , 2014, 124, 1003-1003.	0.6	0
57	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
58	Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group. <i>Blood</i> , 2012, 120, 1452-1452.	0.6	0
59	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1249-1254.	0.6	6
60	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
61	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	1.7	84
62	Myelodysplastic syndromes: an update on molecular pathology. <i>Clinical and Translational Oncology</i> , 2010, 12, 652-661.	1.2	16
63	Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.. <i>Blood</i> , 2009, 114, 1003-1003.	0.6	3
64	Influence of DNA damage and repair upon the risk of treatment related leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 204-217.	0.6	37
65	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008, 111, 3395-3402.	0.6	303
66	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007, 136, 590-596.	1.2	75
67	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1